Agency Forms Undergoing Paperwork Reduction Act Review, 974-975 [2022-00101]
Download as PDF
<![CDATA[
974
Federal Register / Vol. 87, No. 5 / Friday, January 7, 2022 / Notices
CONTESTING RECORD PROCEDURES:
See § 4.13 of the FTC’s Rules of
Practice, 16 CFR 4.13. For additional
guidance, see also Appendix II (How to
Make A Privacy Act Request), available
on the FTC’s website at https://
www.ftc.gov/about-ftc/foia/foia-readingrooms/privacy-act-systems at 73 FR
33592, 33634 (June 12, 2008).
NOTIFICATION PROCEDURES:
See § 4.13 of the FTC’s Rules of
Practice, 16 CFR 4.13. For additional
guidance, see also Appendix II (How to
Make A Privacy Act Request), available
on the FTC’s website at https://
www.ftc.gov/about-ftc/foia/foia-readingrooms/privacy-act-systems at 73 FR
33592, 33634 (June 12, 2008).
EXEMPTIONS PROMULGATED FOR THE SYSTEM:
Records contained in this system that
have been placed on the FTC public
record are available upon request or,
where applicable, made available
online. See FTC–I–6 (Public Records—
FTC). However, pursuant to 5 U.S.C.
552a(k)(2), records in this system, which
reflect records that are contained in
other systems of records that are
designated as exempt, are exempt from
the requirements of subsections (c)(3),
(d), (e)(1), (e)(4)(G), (H), (I), and (f) of 5
U.S.C. 552a. See § 4.13(m) of the FTC
Rules of Practice, 16 CFR 4.13(m).
HISTORY:
*
73 FR 33591–33634 (June 12, 2008).
*
*
*
*
Josephine Liu,
Assistant General Counsel for Legal Counsel.
[FR Doc. 2022–00075 Filed 1–6–22; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[30Day–22–22BJ]
tkelley on DSK125TN23PROD with NOTICE
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Agency for
Toxic Substances and Disease Registry
(ATSDR) has submitted the information
collection request titled Evaluating the
Association between Serum
Concentrations of Per- and
Polyfluoroalkyl substances (PFAS) and
Symptoms and Diagnoses of Selected
Acute Viral Illnesses to the Office of
Management and Budget (OMB) for
review and approval. ATSDR previously
published a ‘‘Proposed Data Collection
VerDate Sep<11>2014
17:08 Jan 06, 2022
Jkt 256001
Submitted for Public Comment and
Recommendations’’ notice on April 5,
2021 to obtain comments from the
public and affected agencies. ATSDR
did not receive comments related to the
previous notice. This notice serves to
allow an additional 30 days for public
and affected agency comments.
ATSDR will accept all comments for
this proposed information collection
project. The Office of Management and
Budget is particularly interested in
comments that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Evaluating the Association between
Serum Concentrations of Per- and
Polyfluoroalkyl Substances (PFAS) and
Symptoms and Diagnoses of Selected
Acute Viral Illnesses—New—Agency for
Toxic Substances and Disease Registry
(ATSDR).
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
Background and Brief Description
Per- and poly-fluoroalkyl substances
(PFAS) are a large, diverse group of
thousands of chemicals that have been
used extensively in a wide range of
industrial and consumer applications.
Epidemiological studies have evaluated
the associations between PFAS
exposure and health effects in humans.
Evidence from these studies in
occupationally exposed populations,
residential populations exposed to
higher levels of PFAS in drinking water,
and studies in the general population
suggest associations between PFAS and
several health outcomes.
Exposure to PFAS is nearly
ubiquitous in the United States.
Epidemiological studies suggest that
PFAS exposure may impact the immune
system and susceptibility to viral
infections. However, there is little
consistency in the results of studies on
PFAS exposure and infectious disease.
The coronavirus disease 2019 (COVID–
19) pandemic presents a unique concern
and opportunity to explore this
association. If PFAS affect the immune
system, it is possible that they could
affect susceptibility to infection with
severe acute respiratory syndrome
coronavirus 2 (SARS–CoV–2), the virus
that causes COVID–19, or could affect
severity of COVID–19 symptoms.
In 2019 and 2020, the Agency for
Toxic Substances and Disease Registry
(ATSDR) conducted statistically based
biomonitoring PFAS exposure
assessments (EAs) in eight communities
that had documented exposures to
PFAS in drinking water. ATSDR also
supported two EAs that were designed
to test the PFAS Exposure Assessment
Technical Tools (PEATT). PFAS
concentrations were measured in serum
collected from EA and PEATT
assessment participants, and a
questionnaire was administered to
gather information to characterize each
individual’s exposure. These
communities were investigated under
‘‘Per- or Polyfluoroalkyl Substances
Exposure Assessments [PFAS EAs]’’
(OMB Control No. 0923–0059,
expiration date 06/30/2022). During the
same period, ATSDR initiated a health
study at the Pease International
Tradeport that included measurement of
PFAS serum levels and collection of
information about individual exposures
in participants under ‘‘Human Health
Effects of Drinking Water Exposures to
Per- and Polyfluoroalkyl Substances
(PFAS) at Pease International Tradeport,
Portsmouth, NH (The Pease Study)’’
(OMB Control No. 0923–0061,
expiration date 08/31/2022).
E:\FR\FM\07JAN1.SGM
07JAN1
975
Federal Register / Vol. 87, No. 5 / Friday, January 7, 2022 / Notices
This a new two-year ATSDR
information collection request (ICR) for
a collaborative study between the
Centers for Disease Control and
Prevention’s National Center for
Environmental Health (CDC/NCEH) and
ATSDR. This follow-up study will
recruit participants who; (1)
participated in a previous ATSDRfunded study, (2) have existing serumPFAS measurements, and (3) have given
prior consent for additional contact
from NCEH/ATSDR. We anticipate that
the total number of participants enrolled
in the CDC/ATSDR cohorts will be
around 3,170 (2,800 adults and 370
children) individuals. This study will
attempt to enroll the entire universe of
eligible participants; therefore, our
target sample size is 3,170. The cohorts
have a substantial number of
participants with high PFAS exposure,
as well as a sufficient range of serumPFAS concentrations to allow
examination of associations between the
outcomes and across a wide range of
PFAS exposures.
The objectives are the following: (1)
To examine the association between
serum-PFAS collected through the EAs,
PEATT assessments, and Pease Study
and the frequency of occurrence of
selected syndromes (combinations of
self-reported symptoms), which will be
used as a proxy for viral infections; and,
(2) to examine the association between
serum-PFAS collected through the EAs,
PEATT assessments, and Pease Study
and self-reported positive test results
indicating specific viral infections.
During the first three months of the
two-year study period, NCEH/ATSDR
will invite and consent approximately
3,170 participants (2,800 adults and 370
children) to complete a new series of
surveys to determine whether PFAS
exposure increases susceptibility to
viral infections, including, but not
limited to COVID–19. Data will be
collected from those who enroll in the
study through an initial paper-based
survey and a series of four additional
surveys over a 12- to 14-month period.
Follow-up surveys will be offered in
two modes: Web-based and paper-based.
It is estimated that 75% of the
participants will choose the web-based
mode. Participants will also be given
symptom diaries to improve recall after
the initial and between each of the
follow-up surveys.
The total time burden requested is
19,816 hours (or 9,908 hours annually).
There are no costs to the respondents
other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Average
burden per
response
(in hours)
Form name
Adults ......................................
Initial Questionnaire—Adult (paper) .......................................
Follow up Questionnaire—Adult (paper) ................................
Follow up Questionnaire—Adult (REDCap) ...........................
Symptom Diary .......................................................................
Initial Questionnaire—Child (paper) .......................................
Follow up Questionnaire—Child (paper) ................................
Follow up Questionnaire—Child (REDCap) ...........................
Symptom Diary .......................................................................
Initial Questionnaire—Child (paper) .......................................
700
175
525
700
70
18
52
70
12
1
4
4
1
1
4
4
1
1
30/60
30/60
25/60
4
30/60
30/60
25/60
4
30/60
Follow up Questionnaire—Child (paper) ................................
Follow up Questionnaire—Child (REDCap) ...........................
Symptom Diary .......................................................................
6
18
23
4
4
1
30/60
25/60
4
Children (7–17 years) .............
Parents of Children (3–6
years).
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2022–00101 Filed 1–6–22; 8:45 am]
BILLING CODE 4163–70–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
tkelley on DSK125TN23PROD with NOTICE
Number of
respondents
Type of respondent
Notice of Award of a Single-Source
Cooperative Agreement To Fund the
Kinshasa School of Public Health,
Democratic Republic of the Congo
(KSPH, DRC)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
AGENCY:
ACTION:
Notice.
VerDate Sep<11>2014
17:08 Jan 06, 2022
Jkt 256001
The Centers for Disease
Control and Prevention (CDC), located
within the Department of Health and
Human Services (HHS), announces the
award of approximately $700,000, with
an expected total funding of $3,500,000
over a five-year period, to the Kinshasa
School of Public Health, Democratic
Republic of the Congo (KSPH DRC). The
award will support the investigation of
the epidemiological, ecological, and
anthropological aspects of monkeypox
and assess clinical intervention
strategies in the Democratic Republic of
Congo (DRC). These activities align with
CDC priorities to promote surveillance
and global health to prevent the
international spread of diseases and to
control them at the source.
DATES: The period for this award will be
September 30, 2022, through September
29, 2027.
FOR FURTHER INFORMATION CONTACT: Dr.
Amy Yang, National Center for HIV,
Viral Hepatitis, STD, and TB Prevention
SUMMARY:
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
(NCHHSTP), Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
MS US8–1, Atlanta, GA 30329–4027,
Telephone: 404–718–8835, Email: corp_
erpo_8835@cdc.gov.
This
single-source award will support the
investigation of the epidemiological,
ecological, and anthropological aspects
of monkeypox and assess clinical
intervention strategies in the DRC.
Research activities will focus on
improvement and evaluation of labbased surveillance systems,
investigations of animal reservoirs and
human behaviors at the human-animal
interface, epidemiologic investigations,
genome sequencing and phylogenetic
analysis, risk mitigation, enhancing
health communication strategies, and
clinical evaluation of vaccines and
therapeutic treatments. The research
should provide the DRC Ministry of
Health and other key stakeholders with
evidence-based strategies to develop
SUPPLEMENTARY INFORMATION:
E:\FR\FM\07JAN1.SGM
07JAN1
]]>Agencies
[Federal Register Volume 87, Number 5 (Friday, January 7, 2022)]
[Notices]
[Pages 974-975]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-00101]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Toxic Substances and Disease Registry
[30Day-22-22BJ]
Agency Forms Undergoing Paperwork Reduction Act Review
In accordance with the Paperwork Reduction Act of 1995, the Agency
for Toxic Substances and Disease Registry (ATSDR) has submitted the
information collection request titled Evaluating the Association
between Serum Concentrations of Per- and Polyfluoroalkyl substances
(PFAS) and Symptoms and Diagnoses of Selected Acute Viral Illnesses to
the Office of Management and Budget (OMB) for review and approval.
ATSDR previously published a ``Proposed Data Collection Submitted for
Public Comment and Recommendations'' notice on April 5, 2021 to obtain
comments from the public and affected agencies. ATSDR did not receive
comments related to the previous notice. This notice serves to allow an
additional 30 days for public and affected agency comments.
ATSDR will accept all comments for this proposed information
collection project. The Office of Management and Budget is particularly
interested in comments that:
(a) Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
(b) Evaluate the accuracy of the agencies estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and clarity of the information to
be collected;
(d) Minimize the burden of the collection of information on those
who are to respond, including, through the use of appropriate
automated, electronic, mechanical, or other technological collection
techniques or other forms of information technology, e.g., permitting
electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570. Comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under 30-day Review--
Open for Public Comments'' or by using the search function. Direct
written comments and/or suggestions regarding the items contained in
this notice to the Attention: CDC Desk Officer, Office of Management
and Budget, 725 17th Street NW, Washington, DC 20503 or by fax to (202)
395-5806. Provide written comments within 30 days of notice
publication.
Proposed Project
Evaluating the Association between Serum Concentrations of Per- and
Polyfluoroalkyl Substances (PFAS) and Symptoms and Diagnoses of
Selected Acute Viral Illnesses--New--Agency for Toxic Substances and
Disease Registry (ATSDR).
Background and Brief Description
Per- and poly-fluoroalkyl substances (PFAS) are a large, diverse
group of thousands of chemicals that have been used extensively in a
wide range of industrial and consumer applications. Epidemiological
studies have evaluated the associations between PFAS exposure and
health effects in humans. Evidence from these studies in occupationally
exposed populations, residential populations exposed to higher levels
of PFAS in drinking water, and studies in the general population
suggest associations between PFAS and several health outcomes.
Exposure to PFAS is nearly ubiquitous in the United States.
Epidemiological studies suggest that PFAS exposure may impact the
immune system and susceptibility to viral infections. However, there is
little consistency in the results of studies on PFAS exposure and
infectious disease. The coronavirus disease 2019 (COVID-19) pandemic
presents a unique concern and opportunity to explore this association.
If PFAS affect the immune system, it is possible that they could affect
susceptibility to infection with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, or could
affect severity of COVID-19 symptoms.
In 2019 and 2020, the Agency for Toxic Substances and Disease
Registry (ATSDR) conducted statistically based biomonitoring PFAS
exposure assessments (EAs) in eight communities that had documented
exposures to PFAS in drinking water. ATSDR also supported two EAs that
were designed to test the PFAS Exposure Assessment Technical Tools
(PEATT). PFAS concentrations were measured in serum collected from EA
and PEATT assessment participants, and a questionnaire was administered
to gather information to characterize each individual's exposure. These
communities were investigated under ``Per- or Polyfluoroalkyl
Substances Exposure Assessments [PFAS EAs]'' (OMB Control No. 0923-
0059, expiration date 06/30/2022). During the same period, ATSDR
initiated a health study at the Pease International Tradeport that
included measurement of PFAS serum levels and collection of information
about individual exposures in participants under ``Human Health Effects
of Drinking Water Exposures to Per- and Polyfluoroalkyl Substances
(PFAS) at Pease International Tradeport, Portsmouth, NH (The Pease
Study)'' (OMB Control No. 0923-0061, expiration date 08/31/2022).
[[Page 975]]
This a new two-year ATSDR information collection request (ICR) for
a collaborative study between the Centers for Disease Control and
Prevention's National Center for Environmental Health (CDC/NCEH) and
ATSDR. This follow-up study will recruit participants who; (1)
participated in a previous ATSDR-funded study, (2) have existing serum-
PFAS measurements, and (3) have given prior consent for additional
contact from NCEH/ATSDR. We anticipate that the total number of
participants enrolled in the CDC/ATSDR cohorts will be around 3,170
(2,800 adults and 370 children) individuals. This study will attempt to
enroll the entire universe of eligible participants; therefore, our
target sample size is 3,170. The cohorts have a substantial number of
participants with high PFAS exposure, as well as a sufficient range of
serum-PFAS concentrations to allow examination of associations between
the outcomes and across a wide range of PFAS exposures.
The objectives are the following: (1) To examine the association
between serum-PFAS collected through the EAs, PEATT assessments, and
Pease Study and the frequency of occurrence of selected syndromes
(combinations of self-reported symptoms), which will be used as a proxy
for viral infections; and, (2) to examine the association between
serum-PFAS collected through the EAs, PEATT assessments, and Pease
Study and self-reported positive test results indicating specific viral
infections.
During the first three months of the two-year study period, NCEH/
ATSDR will invite and consent approximately 3,170 participants (2,800
adults and 370 children) to complete a new series of surveys to
determine whether PFAS exposure increases susceptibility to viral
infections, including, but not limited to COVID-19. Data will be
collected from those who enroll in the study through an initial paper-
based survey and a series of four additional surveys over a 12- to 14-
month period. Follow-up surveys will be offered in two modes: Web-based
and paper-based. It is estimated that 75% of the participants will
choose the web-based mode. Participants will also be given symptom
diaries to improve recall after the initial and between each of the
follow-up surveys.
The total time burden requested is 19,816 hours (or 9,908 hours
annually). There are no costs to the respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondent Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
Adults............................. Initial Questionnaire-- 700 1 30/60
Adult (paper).
Follow up Questionnaire-- 175 4 30/60
Adult (paper).
Follow up Questionnaire-- 525 4 25/60
Adult (REDCap).
Symptom Diary.............. 700 1 4
Children (7-17 years).............. Initial Questionnaire-- 70 1 30/60
Child (paper).
Follow up Questionnaire-- 18 4 30/60
Child (paper).
Follow up Questionnaire-- 52 4 25/60
Child (REDCap).
Symptom Diary.............. 70 1 4
Parents of Children (3-6 years).... Initial Questionnaire-- 12 1 30/60
Child (paper).
Follow up Questionnaire-- 6 4 30/60
Child (paper).
Follow up Questionnaire-- 18 4 25/60
Child (REDCap).
Symptom Diary.............. 23 1 4
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Scientific
Integrity, Office of Science, Centers for Disease Control and
Prevention.
[FR Doc. 2022-00101 Filed 1-6-22; 8:45 am]
BILLING CODE 4163-70-P
